Xenetic Biosciences CF Drug PulmoXen Found To Be Safe, Effective In Cystic Fibrosis Patients
Xenetic Biosciences recently announced that the drug developer’s Phase I clinical trial of its new cystic fibrosis treatment PulmoXen has yielded positive results in the treatment of the disease. The announcement comes as promising news for the 30,000 patients with CF who live in the United States, and who remain…